Skye Bioscience reports results from two preclinical DIO studies on nimacimab

Skye Bioscience (SKYE) reported results from two new preclinical diet induced obesity mouse, DIO, studies evaluating nimacimab, a peripherally-acting CB1-inhibiting monoclonal antibody. The first study measured the efficacy and weight regain dynamics of monlunabant, a small molecule CB1 inhibitor, versus nimacimab, and demonstrated similar or better weight loss than monlunabant, while showing a superior post-treatment maintenance of weight loss, reinforcing a potentially differentiated mechanism. The second study re-evaluated the combination of nimacimab, this time with both optimal and sub-optimal doses of tirzepatide, and continued to show enhanced weight loss effects compared to tirzepatide alone, while also limiting rebound after treatment with tirzepatide is stopped. Importantly, these studies position nimacimab as a potential stand alone, combination and maintenance therapy in the obesity drug development landscape. Key takeaways from Skye’s preclinical DIO data readouts: Nimacimab is differentiated from monlunabant; Nimacimab enhances weight loss when combined with tirzepatide; Nimacimab blunts rebound following treatment with tirzepatide